Israel's Exalenz Diagnostic To Be Used In Pfizer U.S. Hep C Trials
This article was originally published in PharmAsia News
Executive Summary
Exalenz Bioscience of Israel has entered into an agreement with U.S.-based Pfizer to use a diagnostic in a mid-stage trial to treat hepatitis C